| HOME >> MEDICINE >> TECHNOLOGY |
men, suggesting that SHBG is more influenced by the serum E2 and
E2/testosterone ratio than testosterone levels.
-- Interactions of obesity, sex hormone-binding globulin (SHBG) and serum
testosterone in men with low testosterone are complex both at baseline
and after testosterone treatment.
"We are pleased that the AndroGel pivotal data continue to aid physicians and researchers in helping to treat men suffering from the symptoms associated with low testosterone, as we learn more everyday about the appropriate treatments for this patient population," said Dr. Stephen Hill, president and chief executive officer, Solvay Pharmaceuticals, Inc.
About Low Testosterone
It is estimated that hypogonadism, also known as low testosterone, affects more than 13 million men in the United States age 45 and older. Because signs and symptoms of low testosterone are subtle and often overlap with other common medical conditions, low testosterone is frequently undiagnosed. Signs and symptoms of low testosterone include low sex drive, erectile dysfunction, fatigue, depressed mood, reduced muscle mass and strength, increased fat body mass and decreased bone mineral density.
Men with chronic conditions, such as obesity, diabetes, high blood pressure, high cholesterol and asthma/COPD, are also more likely to have low testosterone compared to other men. Below normal levels of testosterone can be confirmed by a blood test. Testosterone treatment is designed to elevate a hypogonadal male's testosterone levels into the normal physiologic range, which may alleviate symptoms related to low testosterone. As with any medication, patients should work with their physician to weigh treatment benefits and risks.
About AndroGel(R)
AndroGel, the first U.S. Food and Drug Administration (FDA)-approved
testosterone gel available in a non-aerosol, metered-dose pump, is a once-
daily, clear, odorless top
'/>"/>
| SOURCE Solvay Pharmaceuticals, Inc. Copyright©2008 PR Newswire. All rights reserved |